Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Provectus Biopharmaceuticals, Inc. Profile picture
Provectus Biopharmaceuticals, Inc.
@ProvectusBio
We are a clinical-stage biotech developing immunotherapy medicines for different diseases based on a class of small molecules called halogenated xanthenes.
David Pincus Profile picture 2 subscribed
Mar 26, 2023 • 7 tweets • 5 min read
1/ 2023 Association for Research in Vision and Ophthalmology Annual Meeting. arvo.org/annual-meeting/. Accepted abstracts from Ophthalmic Biophysics Center about its Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT). #ARVO23 #ARVO2023. @BascomPalmerEye @UMiamiHealth. A… twitter.com/i/web/status/1… 2/ Abstract Number: 606 - B0243. Echeverri Tribin F et al. Inhibition of Multidrug-Resistant Pseudomonas aeruginosa with Rose Bengal Photodynamic Antimicrobial Therapy: In vitro. Conclusions: MDR Pseudomonas aeruginosa can be inhibited by rose bengal eppro02.ativ.me/web/page.php?p…… twitter.com/i/web/status/1…
Mar 25, 2023 • 45 tweets • 20 min read
1/ $PVCT’s Modernized #SmallMolecule #RoseBengal: A #DrugSubstance, and #ActivePharmaceuticalIngredient for 21st Century #DrugDevelopment. A THREAD. 2/ “Everyone” seems to know or understand #RoseBengal, but do they (you) really?
Mar 22, 2023 • 17 tweets • 8 min read
1/ “Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.” $PVCT thoughts: there’s no free lunch. A THREAD. 2/ 20Mar23: Endpoints: “BioNTech to pay $200M upfront in CTLA-4 antibody development, commercialization deal.” endpts.com/biontech-to-pa….
Mar 8, 2023 • 5 tweets • 5 min read
$PVCT-related medical journal article: DePalo DK, Zager JS. Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress. Cancers. 2023; 15(5):1404. doi.org/10.3390/cancer…. @MoffittNews @USFHealthMed. Intralesional agent PV-10… twitter.com/i/web/status/1… DePalo DK, Zager JS. Advances in Intralesional Therapy for L Other $PVCT work by Dr. Zager (and Moffitt Cancer Center) as a principal investigator for us: PV-10 (#RoseBengalSodium) + #Keytruda (#pembrolizumab) for immune checkpoint blockade-naïve Stage III cutaneous melanoma © 2023, Provectus Biopharmaceuticals, Inc. https://www.prov
Mar 6, 2023 • 18 tweets • 7 min read
1/ $PVCT’s PV-10 (#RoseBengalSodium) Immuno-Oncology Cycle & PD-1-Combination Mechanism. A #THREAD. #InduceAndBoost. 2/ Over the past decade-plus, cancer immunotherapy with antibodies targeting the PD-1 immune checkpoint pathway (i.e., PD-1 inhibitors #PD1) has yielded dramatic improvement in clinical outcome for many patients with #CutaneousMelanoma. #Keytruda #Opdivo #otherPD1s #PDL1s
Feb 17, 2023 • 63 tweets • 33 min read
1/ The impact of #Covid on $PVCT’s R&D, #DrugDiscovery, and clinical development of our #HalogenatedXanthene (#HX) medical science platform and #RoseBengalSodium (#RBS) investigational drug & drug formulation pipeline. A #THREAD. 2/ This $PVCT #thread will be an ongoing one for some time. Please check back to read it again (and again), and learn more about our medical scientific history and our lead molecule #RoseBengalSodium’s journey to becoming a multi-disease, broad-spectrum, therapeutic compound.
Jan 27, 2023 • 60 tweets • 26 min read
1/ A $PVCT THREAD: (3) Potential 2023 read outs of preclinical data from sponsored research programs (#SRAs) in different diseases. #research. #oncology #hematology #dermatology #InfectiousDiseases #ophthalmology #WoundHealing #TissueRegeneration. #rosebengal #rosebengalsodium. 2/ $PVCT 2023 Stockholder Letter (released January 9th). . #rosebengal #rosebengalsodium.
Jan 21, 2023 • 50 tweets • 58 min read
1/ A THREAD on what $PVCT achieved in 2022. #event #discovery #milestone #milepost. #rosebengal #rosebengalsodium. 2/ $PVCT 2023 Stockholder Letter (released January 9th). . #rosebengal #rosebengalsodium.
Jan 9, 2023 • 64 tweets • 34 min read
$PVCT Releases 2023 Stockholder Letter globenewswire.com/news-release/2… #rosebengal #rosebengalsodium 1/ $PVCT 2023 Shareholder Letter: (2) Design, prepare, and potentially commence a Phase 2/3 RCT of PV-10®+SOC checkpoint vs monotherapy SOC checkpoint ($MRK #keytruda, $BMY #opdivo) for 1st-line Stage III cutaneous melanoma. #rosebengal #rosebengalsodium. A THREAD.
Dec 20, 2022 • 16 tweets • 5 min read
$PVCT ITU PV-10 v $MRNA cancer vaccine: mRNA produces antigens from a defined library; PV-10 produces antigens present in an injected tumor that may extend beyond what's contained in the library $PVCT ITU PV-10 v $MRNA cancer vaccine: mRNA presumably is based on genomic profiling of a single tumor; PV-10 produces antigens specific to each injected tumor